吡非尼酮治疗慢性移植物抗宿主病相关闭塞性细支气管炎综合征
单臂、开放标签、56周1期试验联合56个月扩展期,评估吡非尼酮在造血干细胞移植后闭塞性细支气管炎综合征患者中的耐受性、安全性和疗效。30例中25例完成56周试验、10例进入扩展期,63%耐受推荐剂量;全部参与者FEV1占预计值百分比显著改善(P=0.00267),41.3%参与者个人肺功能趋势改善。
要点
- 30例中25例完成56周试验,10例进入扩展期,63%耐受推荐剂量且无安全性顾虑。
- 全部参与者FEV1占预计值百分比显著改善(P=0.00267),41.3%参与者个人肺功能趋势改善。
- 肝功能、躯体功能与气促相关患者报告结局及cGVHD皮肤指数显著改善。
核心结论
- 吡非尼酮在造血干细胞移植后BOS患者中安全且可耐受,可能改善肺功能和症状。
- 需进一步试验评估吡非尼酮作为造血干细胞移植后BOS治疗的疗效。
研究设计与样本
- 单臂、开放标签、56周1期试验,并设56个月扩展期,评估吡非尼酮在BOS患者中的耐受性、安全性和疗效。
- 共30例参与者,25例完成56周试验,10例继续进入扩展期。
- 疗效通过肺功能检查、定量计算机断层扫描、患者报告结局、cGVHD指数和实验室检查评估。
- 通过治疗前后回归斜率变化评估肺功能轨迹。
主要发现
- 30例中63%耐受推荐剂量且无安全性顾虑。
- 分析全部参与者时,FEV1占预计值百分比显著改善(P=0.00267)。
- 41.3%参与者个人肺功能趋势改善。
- 按肺叶qCT分析显示应答者上叶肺更健康。
- 肝功能检查、躯体功能与气促相关患者报告结局及cGVHD皮肤指数显著改善。
关键数值与推荐
- 5年生存率为40%。
- 63%参与者耐受推荐剂量且无安全性顾虑。
- 全部参与者FEV1占预计值百分比改善的P=0.00267。
- 41.3%参与者个人肺功能趋势改善。
临床怎么用
- 原文未据此给出推荐。
局限性
- 需进一步试验评估吡非尼酮作为造血干细胞移植后BOS治疗的疗效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Bronchiolitis obliterans syndrome (BOS) is a severe form of chronic graft-versus-host disease (cGVHD) following allogeneic hematopoietic cell transplant (HCT), with a 5-year survival rate of 40%. Currently, there is no curative therapy for BOS. Preclinical data suggest that pirfenidone, an antifibrotic drug, may benefit small airway fibrosis in HCT-associated BOS. A single-arm, open-label, 56-week phase 1 trial with 56-month extension evaluated pirfenidone's tolerability, safety, and efficacy in patients with BOS. Efficacy was measured using pulmonary function tests (PFTs), quantitative computed tomography (qCT) scans, patient-reported outcomes (PROs), cGVHD indices, and laboratory tests. Lung function trajectory was assessed by change in regression slopes before and during treatment. Baseline qCT metrics, including percentage normal lung, air trapping, volume change (Jacobian), and heterogeneity of volume change (Jacobian variance), were analyzed by participant response. Of 30 participants, 25 completed the 56-week trial, and 10 continued into the extension. Overall, 63% tolerated the recommended dose without safety concerns. There was significant improvement in the percent predicted forced expiratory volume in 1 second (P = .00267) when analyzing all participants, and improvement in individual PFT trend for 41.3% of participants. qCT analysis by lobe showed healthier lungs in the upper lobes of responders. Significant improvements were noted in liver function tests, PROs related to physical functioning and shortness of breath, and cGVHD skin indices. These findings indicate that pirfenidone is safe and tolerable in patients with BOS after HCT and may improve lung function and symptoms. Further trials are warranted to evaluate the efficacy of pirfenidone as a treatment for BOS after HCT. This trial was registered at www.ClinicalTrials.gov as #NCT03315741.
引用
- Sharifi H, Moss CT, Musa Z, et al. Pirfenidone for the treatment of bronchiolitis obliterans syndrome related to chronic graft-versus-host disease. Blood Adv. 2025. PMID: 40554417. doi:10.1182/bloodadvances.2025016122
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。